-- Introduces new panels for Parkinson’s
disease, neuropathies, and neuromuscular diseases --
-- Adds new genes to panels for arrhythmias,
cardiomyopathies, aortopathies, and congenital heart disease;
introduces a new cardiomyopathy and skeletal muscle disease panel
--
Invitae Corporation (NYSE: NVTA), a genetic information company,
today announced that it has expanded its neurology and cardiology
test offering, adding 11 new panels for heritable diseases. In
addition, Invitae has updated 17 existing neurology panels and
eight cardiology panels based on new discoveries in genetics
research.
With this latest expansion of its test offerings, Invitae will
be able to provide clinicians, patients, and payers with even
higher-quality information on genetic changes that have been shown
to influence a variety of neurologic and cardiovascular disorders –
for the same price and with the same three-week average turnaround
time. The new panels will be available immediately to children’s
hospitals, pediatricians, and medical genetics professionals for
clinical diagnosis and care.
“Invitae is steadfast in its commitment to making high-quality
genetic tests based on the latest clinical and scientific evidence
available to patients and their family members,” said Robert
Nussbaum, MD, chief medical officer of Invitae. “The launch of our
new and updated panels clearly illustrates our ongoing dedication
to careful and comprehensive gene curation.”
Expanded neurology testing
With this expanded neurology offerings, Invitae provides
clinicians, patients, and payers with more options for
high-quality, affordable genetic testing, including:
- Invitae’s Hereditary Parkinson’s
Disease & Parkinsonism Panel – analyzing up to 17 genes
associated with Parkinson’s disease and related conditions
involving Parkinsonian features
- Invitae’s Comprehensive Neuropathies
Panel – 78 genes covering Charcot-Marie-Tooth (CMT) disease,
hereditary motor neuropathies, hereditary sensory and autonomic
neuropathy, and riboflavin transporter deficiency neuronopathy
- Invitae’s Comprehensive Neuromuscular
Disorders Panel – 116 genes covering muscular dystrophy, myopathy,
and congenital myasthenic syndrome
- Additional myopathy panels, including a
hyperkalemic periodic paralysis test, a hypokalemic periodic
paralysis panel, an inclusion body myopathy panel, and an
autophagic vacuolar myopathy panel
- Additional neuropathy panels, including
hereditary sensory and autonomic neuropathy panels, a hereditary
motor neuropathies panel, and a riboflavin transporter deficiency
neuronopathy panel
- Updates to existing panels to
incorporate the latest research findings:
- 13 new genes for the comprehensive CMT
panel for a total of 45 genes
- 20 new genes for the comprehensive
hereditary spastic paraplegia (HSP) panel for a total of 63
genes
- Updates to 15 additional panels across
our neurology offering
"Genetic testing for hereditary Parkinson's disease has
fundamentally changed the way in which we look at providing answers
to families affected with this devastating condition," said J.
William Langston, MD, chief scientific officer and founder of the
Parkinson's Institute and Clinical Center. "My hope is for every
person with early-onset Parkinson's or a family history of the
disease be provided the opportunity to have genetic testing, so we
can work together to develop better treatments and improve
healthcare for everyone."
Invitae’s latest expansion of its test offering is based on the
latest research findings in genetics across various panels. For
example, three peer-reviewed papers published in the past year show
evidence that the MORC2 gene causes CMT disease, and therefore was
added to Invitae’s comprehensive CMT panel:
- Sevilla T, et al. Mutations in the
MORC2 gene cause axonal Charcot-Marie-Tooth disease. Brain. 2016
Jan;139(Pt 1):62-72. doi: 10.1093/brain/awv311
- Albulym OM, et al. MORC2 mutations
cause axonal Charcot-Marie-Tooth disease with pyramidal signs. Ann
Neurol. 2016 Mar;79(3):419-27. doi: 10.1002/ana.24575
- Laššuthová P, et al. Severe axonal
Charcot-Marie-Tooth disease with proximal weakness caused by de
novo mutation in the MORC2 gene. Brain. 2016 Apr;139(Pt 4):e26.
doi: 10.1093/brain/awv411
“We are excited to see the addition of new genes in Invitae’s
CMT panel,” said Susan Ruediger, patient advocate and Director of
Development at the Charcot-Marie-Tooth Association (CMTA).
“Comprehensive genetic testing can provide patients with a
definitive diagnosis, which is critical for the treatment and
management of the disease.”
Cardiovascular panels aligned to new research
Understanding of the genetic links to cardiovascular disease is
rapidly advancing. Invitae has expanded eight existing cardiology
panels to reflect recent advances in the field to provide
comprehensive, evidence-based test options for diagnosing
aortopathies, arrhythmias, cardiomyopathies, and pulmonary
hypertension. Additionally, Invitae has added a new cardiomyopathy
and skeletal muscle disease panel for patients who exhibit
overlapping features of both heart and skeletal muscle disorders
that analyzes up to 157 genes associated with neuromuscular
disorders and cardiomyopathies.
“The role of genetic testing in diagnosing cardiovascular
disease is rapidly expanding, now offering us insights that can
help patients with a variety of conditions, such as dilated
cardiomyopathy and primary arrhythmias,” said Ray Hershberger, MD,
professor of cardiovascular medicine and director of the division
of human genetics at The Ohio State University Wexner Medical
Center. “Importantly, genetic testing can also help us understand
when cardiac problems are actually the first symptoms of a broader
genetic disease. Expanding our ability to access clear and
comprehensive genetic information will help us better diagnose and
treat patients.”
This expanded offering includes state-of-art cardiovascular
genetic testing with panels expertly curated and updated by medical
and genetics experts. The Invitae Cardiomyopathy and Skeletal
Muscle Disease Panel is a convenient and economical option for
patients presenting with overlapping features associated with
cardiomyopathies and muscular dystrophies that typically require
multiple test orders.
Affordable, transparent pricing
Invitae offers a transparent pricing structure independent of
the number of genes required to provide an accurate diagnosis
within a single clinical area. For payers and institutions that are
in contract with Invitae, the price per clinical area can be as low
as $950, depending on the payer’s requirements. For third-party
payers with whom Invitae is out-of-network and for non-contracted
institutions, the price per clinical area is $1,500. In addition,
for patients without third-party insurance coverage or who do not
meet insurance criteria for coverage, Invitae offers its full test
offerings for $475 per clinical area (see website for more
details).
About Invitae
Invitae Corporation's (NYSE: NVTA) mission is to bring
comprehensive genetic information into mainstream medical practice
to improve the quality of healthcare for billions of people.
Invitae’s goal is to aggregate most of the world’s genetic tests
into a single service with higher quality, faster turnaround time,
and lower price than many single-gene and panel tests today. The
company currently provides a diagnostic service comprising hundreds
of genes for a variety of genetic disorders associated with
oncology, cardiology, neurology, pediatrics, and other rare disease
areas. For more information, visit our website at invitae.com.
Safe Harbor Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the availability of the
company’s new panels; the effect of the company’s expansion of its
test menu and its ability to provide higher quality information on
genetic changes; and that such information will lead to better
diagnoses and treatments for patients. Forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to: risks associated
with the company’s ability to use rapidly changing genetic data to
interpret test results accurately, consistently and quickly; the
company’s ability to develop and commercialize new tests and expand
into new markets; the company’s history of losses; the company’s
need to scale its infrastructure in advance of demand for its tests
and to increase demand for its tests; the risk that the company may
not obtain or maintain sufficient levels of reimbursement for its
tests; laws and regulations applicable to the company’s business,
including state licensing requirements and potential regulation by
the Food and Drug Administration; and the other risks set forth in
the company’s filings with the Securities and Exchange Commission,
including the risks set forth in the company’s Quarterly Report on
Form 10-Q for the quarter ended June 30, 2016. These
forward-looking statements speak only as of the date hereof, and
Invitae Corporation disclaims any obligation to update these
forward-looking statements.
NOTE: Invitae and the Invitae logo are trademarks of Invitae
Corporation. All other trademarks and service marks are the
property of their respective owners.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160815005210/en/
Invitae CorporationLaura D’Angelo,
314-920-0617pr@invitae.com
Invitae (NYSE:NVTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Invitae (NYSE:NVTA)
Historical Stock Chart
From Apr 2023 to Apr 2024